$THC
TENET HEALTHCARE CORP Stock $thc

$thc Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000007031824000032 Filed on April 30, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$5.103B	$5.368B
YoY Change	0.41%	6.91%
Cost Of Revenue	$908.0M	$928.0M
YoY Change	1.91%	4.15%
Gross Profit	$4.195B	$4.440B
YoY Change	0.1%	7.51%
Gross Profit Margin	82.21%	82.71%
Selling, General & Admin	$2.168B	$2.321B
YoY Change	-5.12%	2.79%
% of Gross Profit	51.68%	52.27%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$208.0M	$208.0M
YoY Change	-2.35%	-4.15%
% of Gross Profit	4.96%	4.68%
Operating Expenses	$3.524B	$3.613B
YoY Change	0.0%	3.91%
Operating Profit	$671.0M	$827.0M
YoY Change	0.6%	37.15%
Interest Expense	-$142.0M	-$159.0M
YoY Change	-17.44%	-171.95%
% of Operating Profit	-21.16%	-19.23%
Other Income/Expense, Net	$29.00M	$25.00M
YoY Change	383.33%	-1350.0%
Pretax Income	$587.0M	$3.084B
YoY Change	57.37%	711.58%
Income Tax	$110.0M	$750.0M
% Of Pretax Income	18.74%	24.32%
Net Earnings	$259.0M	$2.151B
YoY Change	110.57%	626.69%
Net Earnings / Revenue	5.08%	40.07%
Basic Earnings Per Share	$2.66	$21.60
Diluted Earnings Per Share	$2.63	$21.38
COMMON SHARES
Basic Shares Outstanding	97.68M shares	100.0M shares
Diluted Shares Outstanding	98.44M shares	100.6M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.880B	$2.481B
YoY Change	208.35%	223.89%
Cash & Equivalents	$2.880B	$2.481B
Short-Term Investments
Other Short-Term Assets	$1.876B	$1.048B
YoY Change	64.71%	-37.28%
Inventory	$382.0M	$395.0M
Prepaid Expenses	$379.0M	$375.0M
Receivables	$2.817B	$3.342B
Other Receivables	$0.00	$555.0M
Total Short-Term Assets	$7.955B	$7.821B
YoY Change	32.69%	33.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.857B	$5.855B
YoY Change	-6.56%	-7.34%
Goodwill	$10.80B	$10.57B
YoY Change	4.34%	3.02%
Intangibles	$1.413B	$1.399B
YoY Change	0.5%	-2.3%
Long-Term Investments	$3.156B	$3.244B
YoY Change	0.83%	2.17%
Other Assets	$85.00M	$20.00M
YoY Change	962.5%	42.86%
Total Long-Term Assets	$21.31B	$21.09B
YoY Change	0.7%	-0.53%
TOTAL ASSETS
Total Short-Term Assets	$7.955B	$7.821B
Total Long-Term Assets	$21.31B	$21.09B
Total Assets	$29.27B	$28.91B
YoY Change	7.76%	6.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.270B	$1.335B
YoY Change	1.93%	12.0%
Accrued Expenses	$937.0M	$1.024B
YoY Change	2.18%	20.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$102.0M	$107.0M
YoY Change	-27.66%	-27.7%
Total Short-Term Liabilities	$5.493B	$5.416B
YoY Change	32.3%	28.37%
LONG-TERM LIABILITIES
Long-Term Debt	$12.77B	$12.77B
YoY Change	-14.34%	-14.48%
Other Long-Term Liabilities	$2.889B	$2.817B
YoY Change	1.23%	61.16%
Total Long-Term Liabilities	$15.66B	$15.59B
YoY Change	-11.84%	791.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.493B	$5.416B
Total Long-Term Liabilities	$15.66B	$15.59B
Total Liabilities	$25.79B	$25.45B
YoY Change	-0.09%	14.34%
SHAREHOLDERS EQUITY
Retained Earnings	$2.218B	$1.959B
YoY Change	-513.04%	-396.82%
Common Stock	$8.000M	$8.000M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.475B	$3.453B
YoY Change
Total Liabilities & Shareholders Equity	$29.27B	$28.91B
YoY Change	7.76%	6.8%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$259.0M	$2.151B
YoY Change	110.57%	626.69%
Depreciation, Depletion And Amortization	$208.0M	$208.0M
YoY Change	-2.35%	-4.15%
Cash From Operating Activities	$747.0M	$586.0M
YoY Change	24.92%	30.51%
INVESTING ACTIVITIES
Capital Expenditures	$145.0M	$240.0M
YoY Change	9.85%	2.13%
Acquisitions		$449.0M
YoY Change		835.42%
Other Investing Activities	-$49.00M	$3.568B
YoY Change	0.0%	50871.43%
Cash From Investing Activities	-$194.0M	$3.328B
YoY Change	7.18%	-1263.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-154.0M	-2.661B
YoY Change	-38.15%	943.53%
NET CHANGE
Cash From Operating Activities	747.0M	586.0M
Cash From Investing Activities	-194.0M	3.328B
Cash From Financing Activities	-154.0M	-2.661B
Net Change In Cash	399.0M	1.253B
YoY Change	137.5%	-1461.96%
FREE CASH FLOW
Cash From Operating Activities	$747.0M	$586.0M
Capital Expenditures	$145.0M	$240.0M
Free Cash Flow	$602.0M	$346.0M
YoY Change	29.18%	61.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P9M
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	3000000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	59000000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	50000000	usd
CY2024Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2321000000	usd
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2258000000	usd
CY2024Q1	us-gaap	Supplies Expense SuppliesExpense	928000000	usd
CY2023Q1	us-gaap	Supplies Expense SuppliesExpense	891000000	usd
CY2024Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1154000000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1093000000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	208000000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217000000	usd
CY2024Q1	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	27000000	usd
CY2023Q1	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	21000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3285000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	603000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	218000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	221000000	usd
CY2024Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-4000000	usd
CY2023Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-4000000	usd
CY2024Q1	thc	Net Gains Losses On Sale Consolidation And Deconsolidation Of Facilities NetGainsLossesOnSaleConsolidationAndDeconsolidationOfFacilities	2500000000	usd
CY2023Q1	thc	Net Gains Losses On Sale Consolidation And Deconsolidation Of Facilities NetGainsLossesOnSaleConsolidationAndDeconsolidationOfFacilities	13000000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8000000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	3084000000	usd
CY2023Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	380000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	750000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2334000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	296000000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	183000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	153000000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2151000000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	143000000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	21.60
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.40
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	21.38
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99581000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102289000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100598000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106006000	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2334000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	296000000	usd
CY2024Q1	thc	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Amortization Of Net Actuarial Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax	2000000	usd
CY2023Q1	thc	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Amortization Of Net Actuarial Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAmortizationOfNetActuarialGainLossArisingDuringPeriodBeforeTax	2000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	1000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	3000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	2000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2336000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	298000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	183000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	153000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2153000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	145000000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	208000000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217000000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-38000000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	8000000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	17000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14000000	usd
CY2024Q1	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	27000000	usd
CY2023Q1	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	21000000	usd
CY2024Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-4000000	usd
CY2023Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-4000000	usd
CY2024Q1	thc	Net Losses On Sale Consolidation And Deconsolidation Of Facilities NetLossesOnSaleConsolidationAndDeconsolidationOfFacilities	2500000000	usd
CY2023Q1	thc	Net Losses On Sale Consolidation And Deconsolidation Of Facilities NetLossesOnSaleConsolidationAndDeconsolidationOfFacilities	13000000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8000000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-3000000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-11000000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8000000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9000000	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	14000000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5000000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	263000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-35000000	usd
CY2024Q1	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	18000000	usd
CY2023Q1	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	-50000000	usd
CY2024Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-783000000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-76000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	19000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-230000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	24000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-9000000	usd
CY2024Q1	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	25000000	usd
CY2023Q1	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	24000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	586000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	449000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	240000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	235000000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	449000000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	48000000	usd
CY2024Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	4030000000	usd
CY2023Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	13000000	usd
CY2024Q1	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	7000000	usd
CY2023Q1	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	9000000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10000000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	18000000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	10000000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	7000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3328000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-286000000	usd
CY2024Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	2141000000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	45000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	12000000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	278000000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000000	usd
CY2024Q1	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	162000000	usd
CY2023Q1	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	134000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Interest In Corporate Unit ProceedsFromSaleOfInterestInCorporateUnit	5000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Interest In Corporate Unit ProceedsFromSaleOfInterestInCorporateUnit	25000000	usd
CY2024Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	52000000	usd
CY2023Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	41000000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-35000000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-22000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2661000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-255000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1253000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-92000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1228000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	858000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2481000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	766000000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	162000000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	177000000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5000000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2481000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1228000000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	57000000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	154000000	usd
CY2024Q1	thc	Finance Lease Right Of Use Assets Acquired FinanceLeaseRightOfUseAssetsAcquired	14000000	usd
CY2023Q1	thc	Finance Lease Right Of Use Assets Acquired FinanceLeaseRightOfUseAssetsAcquired	19000000	usd
CY2024Q1	thc	Operating Lease Right Of Use Assets Acquired OperatingLeaseRightOfUseAssetsAcquired	41000000	usd
CY2023Q1	thc	Operating Lease Right Of Use Assets Acquired OperatingLeaseRightOfUseAssetsAcquired	44000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1990000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1312000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	678000000	usd
CY2024Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	721000000	usd
CY2024Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	721000000	usd
CY2024Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2711000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1312000000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1399000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2097000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1447000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	650000000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	718000000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	718000000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2815000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1447000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1368000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	678000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	125000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	111000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	99000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	88000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	66000000	usd
CY2024Q1	thc	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	189000000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	45000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42000000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	375000000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	391000000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	194000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	208000000	usd
CY2024Q1	thc	Receivables From Government Programs Current ReceivablesFromGovernmentProgramsCurrent	240000000	usd
CY2023Q4	thc	Receivables From Government Programs Current ReceivablesFromGovernmentProgramsCurrent	282000000	usd
CY2024Q1	thc	Physician And Group Coverage Guarantees Current PhysicianAndGroupCoverageGuaranteesCurrent	248000000	usd
CY2023Q4	thc	Physician And Group Coverage Guarantees Current PhysicianAndGroupCoverageGuaranteesCurrent	274000000	usd
CY2024Q1	us-gaap	Other Receivables OtherReceivables	315000000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	260000000	usd
CY2024Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	98000000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	95000000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1775000000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1839000000	usd
CY2024Q1	thc	Percentage Investee Results Reflected PercentageInvesteeResultsReflected	1
CY2024Q1	us-gaap	Health Care Organization Health Care Costs Gross HealthCareOrganizationHealthCareCostsGross	160000000	usd
CY2023Q1	us-gaap	Health Care Organization Health Care Costs Gross HealthCareOrganizationHealthCareCostsGross	147000000	usd
CY2024Q1	thc	Contract With Customer Asset Percentage To Be Reclassified To Receivable Within90 Days ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days	0.87
CY2023Q4	thc	Contract With Customer Asset Percentage To Be Reclassified To Receivable Within90 Days ContractWithCustomerAssetPercentageToBeReclassifiedToReceivableWithin90Days	0.87
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	52000000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	64000000	usd
CY2024Q1	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	21000000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	22000000	usd
CY2024Q1	us-gaap	Income Loss From Individually Significant Component Disposed Of Or Held For Sale Excluding Discontinued Operations Before Income Tax IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax	2516000000	usd
CY2023Q1	us-gaap	Income Loss From Individually Significant Component Disposed Of Or Held For Sale Excluding Discontinued Operations Before Income Tax IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax	52000000	usd
CY2024Q1	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	27000000	usd
CY2024Q1	us-gaap	Restructuring Costs RestructuringCosts	14000000	usd
CY2024Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	12000000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1000000	usd
CY2024Q1	us-gaap	Other Restructuring Costs OtherRestructuringCosts	4000000	usd
CY2023Q1	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	21000000	usd
CY2023Q1	us-gaap	Restructuring Costs RestructuringCosts	18000000	usd
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2000000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1000000	usd
CY2023Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	3000000	usd
CY2023Q1	us-gaap	Other Restructuring Costs OtherRestructuringCosts	3000000	usd
CY2023Q1	thc	Business Combination Acquisition Related Transaction Costs BusinessCombinationAcquisitionRelatedTransactionCosts	2000000	usd
CY2024Q1	thc	Finance Leases And Mortgage Notes FinanceLeasesAndMortgageNotes	324000000	usd
CY2023Q4	thc	Finance Leases And Mortgage Notes FinanceLeasesAndMortgageNotes	361000000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	107000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	121000000	usd
CY2024Q1	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	12879000000	usd
CY2023Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	15002000000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	107000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	120000000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	12772000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	14882000000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17000000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3117000000	usd
CY2024Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	2233000000	usd
CY2024Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	78000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2000000	usd
CY2024Q1	thc	Adjustments To Additional Paid In Capital Purchase Sale Of Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfNoncontrollingInterests	-28000000	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	280000000	usd
CY2024Q1	thc	Shares Issued And Share Based Compensation Expense Value Share Based Payment Arrangement After Forfeiture SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture	-23000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4943000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2459000000	usd
CY2023Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	217000000	usd
CY2023Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	61000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2000000	usd
CY2023Q1	thc	Adjustments To Additional Paid In Capital Purchase Sale Of Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalPurchaseSaleOfNoncontrollingInterests	19000000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	50000000	usd
CY2023Q1	thc	Shares Issued And Share Based Compensation Expense Value Share Based Payment Arrangement After Forfeiture SharesIssuedAndShareBasedCompensationExpenseValueShareBasedPaymentArrangementAfterForfeiture	-6000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2580000000	usd
CY2022Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	1000000000	usd
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0
CY2024Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	550000000	usd
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0
CY2024Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	550000000	usd
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	2811000	shares
CY2024Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	98.86
CY2024Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	272000000	usd
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2023Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0
CY2023Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	750000000	usd
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2023Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0
CY2023Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	750000000	usd
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	906000	shares
CY2023Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	55.03
CY2023Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	700000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5854000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	513000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	684000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	683000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	683000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	683000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2608000000	usd
	thc	Insurance Annual Coverage Limit InsuranceAnnualCoverageLimit	850000000	usd
CY2023Q1	us-gaap	Insurance Recoveries InsuranceRecoveries	31000000	usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	2728000000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	2391000000	usd
CY2024Q1	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	101000000	usd
CY2023Q1	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	79000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	750000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3084000000.000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	380000000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	648000000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	80000000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	203000000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	16000000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	38000000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	32000000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	126000000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5000000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2000000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-185000000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19000000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1000000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	750000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-185000000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19000000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	61000000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	59000000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	1000000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	3000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2151000000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99581000	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	21.60
CY2024Q1	us-gaap	Dilutive Securities DilutiveSecurities	0	usd
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1017000	shares
CY2024Q1	thc	Effect Of Dilutive Securities Per Share Amount EffectOfDilutiveSecuritiesPerShareAmount	-0.22
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2151000000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100598000	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	21.38
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	143000000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102289000	shares
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.40
CY2023Q1	us-gaap	Dilutive Securities DilutiveSecurities	-3000000	usd
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3717000	shares
CY2023Q1	thc	Effect Of Dilutive Securities Per Share Amount EffectOfDilutiveSecuritiesPerShareAmount	-0.08
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	140000000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106006000	shares
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.32
CY2024Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss	-4000000	usd
CY2023Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss	13000000	usd
CY2024Q1	thc	Business Combination Acquisition Related Transaction Costs BusinessCombinationAcquisitionRelatedTransactionCosts	12000000	usd
CY2023Q1	thc	Business Combination Acquisition Related Transaction Costs BusinessCombinationAcquisitionRelatedTransactionCosts	2000000	usd
CY2024Q1	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-11000000	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2024Q1	us-gaap	Assets Assets	28907000000	usd
CY2023Q4	us-gaap	Assets Assets	28312000000	usd
CY2024Q1	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1024000000	usd
CY2023Q1	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	832000000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	208000000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217000000	usd
CY2024Q1	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	27000000	usd
CY2023Q1	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	21000000	usd
CY2024Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-4000000	usd
CY2023Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-4000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	218000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	221000000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8000000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000000	usd
CY2024Q1	thc	Net Gains Losses On Sale Consolidation And Deconsolidation Of Facilities NetGainsLossesOnSaleConsolidationAndDeconsolidationOfFacilities	2500000000	usd
CY2023Q1	thc	Net Gains Losses On Sale Consolidation And Deconsolidation Of Facilities NetGainsLossesOnSaleConsolidationAndDeconsolidationOfFacilities	13000000	usd
CY2024Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	3084000000	usd
CY2023Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	380000000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000070318-24-000032-index-headers.html	Edgar Link	pending
0000070318-24-000032-index.html	Edgar Link	pending
0000070318-24-000032.txt	Edgar Link	pending
0000070318-24-000032-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thc-20240331.htm	Edgar Link	pending
thc-20240331.xsd	Edgar Link	pending
thc-20240331x10qxex10a.htm	Edgar Link	pending
thc-20240331x10qxex10b.htm	Edgar Link	pending
thc-20240331x10qxex31a.htm	Edgar Link	pending
thc-20240331x10qxex31b.htm	Edgar Link	pending
thc-20240331x10qxex32.htm	Edgar Link	pending
thc-20240331_def.xml	Edgar Link	unprocessable
thc-20240331_lab.xml	Edgar Link	unprocessable
thc-20240331_pre.xml	Edgar Link	unprocessable
thc-20240331_htm.xml	Edgar Link	completed
thc-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THC
TENET HEALTHCARE CORP Stock $thc

2024 Q2 Form 10-Q Financial Statement

#000007031824000032 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC TENET HEALTHCARE CORP Stock $thc

2024 Q2 Form 10-Q Financial Statement

#000007031824000032 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC
TENET HEALTHCARE CORP Stock $thc